Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a Outperform recommendation. Analyst Price Forecast Suggests 353.70% Upside As ...

As a Black, queer, transmasculine, gender expansive, polyamorous, and kinky healing practitioner Syre (he/him) is passionate about working with those who are traditionally marginalized ...